This post was originally published on this site Two compounds found in coffee might be able to slow the growth and migration of prostate cancers, a pilot study conducted in drug-resistant cancer cells and a mouse model report. As such, two possible therapeutic candidates for drug-resistant prostate cancers may have been identified in this work,…
About Cancer
Cancer, also called malignancy, is an abnormal growth of cells with the potential to invade or spread to surrounding tissues and structures found within the body. There are more than 100 types of cancer. A few examples include breast cancer, skin cancer, lung cancer, colon cancer, prostate cancer, and lymphoma. According to the American Cancer Society, 4 out of 10 people will be diagnosed with some form of cancer in their lifetime. Cancer prevalence has given rise to multiple medical specialties focused on symptom management and disease management. Current treatment options depending on the form of cancer include chemotherapy, radiation, blood or bone marrow transfusions, and/or surgery. Lifetime prognosis of cancer mortality is dependent on the type of cancer and is heavily conditional to early detection.
Conditions
Cancer News
Study Targets Activity, Oxygen Issues in Advanced Sarcoidosis Patients
This post was originally published on this site Patients with advanced sarcoidosis have limited daily life physical activity, mostly because their lungs’ maximal oxygen uptake is reduced, a study shows. The findings of the study, “Daily life physical activity in patients with chronic stage IV sarcoidosis: A multicenter cohort study,” were published in the journal Health…
TG Therapeutics’ Umbralisib Proves Safe, Effective for Previously Treated Marginal Zone Lymphoma
This post was originally published on this site TG Therapeutics‘ umbralisib (TGR-1202), an inhibitor of the PI3K delta protein, has shown promising efficacy and safety in patients with relapsed or refractory marginal zone lymphoma, reducing cancer volume in more than half of patients in a Phase 2b trial. Findings from the ongoing trial — called UNITY-NHL (NCT02793583) — were presented at the American…
Radioactive Compound Shows Promise as Therapy for Metastatic Castration-resistant Prostate Cancer Patients
This post was originally published on this site Treatment with the radioactive molecule lutetium-177-PSMA-617 (LuPSMA), which binds to the prostate-specific membrane antigen, is a potential therapeutic strategy for patients with metastatic castration-resistant prostate cancer (CRPC), results from a pilot study suggest. The findings were shared in the poster, “Results of a 50 patient single-centre phase…
DPX-Survivac Treatment Continues to Show Promise in Women with Advanced Ovarian Cancer, Early Data Show
This post was originally published on this site Treatment with DPX-Survivac plus intermittent low-dose cyclophosphamide continues to show promise in women with advanced recurrent ovarian cancer, the second part of a Phase 1/2 trial shows. Interim data from the first six patients revealed that five patients (83%) achieved stable disease, including two tumor regressions —…
European Panel OKs Approval of Triple Combination Therapies for Multiple Myeloma Patients
This post was originally published on this site The European Medicines Agency‘s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended approval of Celgene‘s Revlimid (lenalidomide) and Pomalyst (pomalidomide, marketed as Imnovid in Europe) as combination therapies with Velcade (bortezomib) and dexamethasone for adult patients with multiple myeloma. In the case of Revlimid, the triple…
Phase 1 Study Begins Dosing High-Grade Glioma Patients with GMCI Combo Therapy
This post was originally published on this site A Phase 1 study has started dosing patients who have newly diagnosed high-grade gliomas with a combination of Candel Therapeutics‘ gene-mediated cytotoxic immunotherapy (GMCI) plus Opdivo (nivolumab) and standard of care therapy. GMCI (aglatimagene besadenovec plus prodrug) is an “off-the-shelf” adenovirus-based medicine meant to increase the amount…
FDA Proposes New Policies to Modernize, Improve Quality of Mammography Screenings
This post was originally published on this site The U.S. Food and Drug Administration (FDA) has proposed a set of new policies to modernize and improve the quality of mammography screenings for breast cancer. The federal agency is confident that such measures may help women facing the disease make informed decisions about their health care.…
Leukemia & Lymphoma Society’s Silicon Valley Chapter Raises $297K in ‘Student of the Year’ Contest
This post was originally published on this site The Leukemia & Lymphoma Society’s (LLS) Silicon Valley Student of the Year drive netted more than $297,000 to support the organization’s research and patient support efforts. Funds were raised through the LLS’ Silicon Valley & Monterey Bay Area chapter by some 39 high school students. The top fundraisers were Evergreen…
INB03 May Help Reverse Cancer’s Resistance to Immunotherapy, INmune Bio Co-founder Says
This post was originally published on this site Therapy candidate INB03, meant to inactivate a kind immunosuppressive cell called myeloid-derived suppressor cells (MDSCs) while boosting anti-tumor immune cells, may help overcome resistance to immunotherapies, including immune checkpoint inhibitors, INmune Bio’s co-founder Raymond J. Tesi, MD, said at a conference. Tesi, CEO of INmune Bio, presented the potentialities…
Doc, You’re a Downer. Let Me Revel in My 5-Year Mark
This post was originally published on this site I met a guy at a party. At first, he was quite the charmer, one of those middle-aged guys who was the most popular guy in high school. Standing within his orbit, I felt like I’d been invited to join the cool kids’ cafeteria table and everyone…
Targazyme Gets Funding for Trial Testing TZ101 for Erectile Dysfunction in PC Patients
This post was originally published on this site Targazyme has been granted an award from the The Sexual Medicine Society of North America that will fund a clinical trial testing the company’s stem cell-based product TZ101 to reverse erectile dysfunction in prostate cancer patients. The study will be conducted at The University of Texas Health…